Kestra Medical Technologies, Ltd. (KMTS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-619.4%

-$154.84

vs $29.81 price

Levered DCF

-$273.30

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

5.31

Safe zone

Rating

D+

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2021	FY2020
P/E	-8.53×	-4.69×	-10.71×	-12.48×	-12.77×	-37.02×
P/B	4.66×	5.8×	-5.17×	-9.2×	245.92×	280.48×
P/S	12.72×	19.92×	38.89×	141.78×	0×	0×
EV / EBITDA	-8.45×	-10.19×	-14.66×	-15×	-13.39×	-37.33×
Gross margin	51.4%	40.5%	1.3%	-139.6%	0.0%	0.0%
Operating margin	-141.6%	-177.8%	-305.8%	-1054.0%	0.0%	0.0%
Net margin	-138.4%	-190.3%	-338.4%	-1104.0%	0.0%	0.0%
Current ratio	4.41×	6.72×	0.45×	0.5×	3.96×	1.54×
Debt / equity	0.18×	0.22×	-0.22×	-0.33×	12.94×	0.12×
Interest coverage	-17.85×	-13.75×	-13.65×	-14.29×	-28×	0×
Dividend yield	0.0%	0.1%	0.1%	0.1%	0.0%	0.0%
Payout ratio	-0.2%	-1.5%	-0.8%	-0.8%	-0.5%	-0.6%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2021	FY2020
Return on equity	-50.7%	-55.4%	45.0%	71.6%	-1931.0%	-764.0%
Return on invested capital	-43.7%	-41.2%	-655.4%	-338.9%	-131.0%	-680.4%
Return on assets	-36.7%	-38.5%	-204.8%	-217.9%	-111.7%	-374.3%
Free cash flow yield	-9.6%	-8.5%	-7.8%	-7.9%	-7.0%	-2.8%
Earnings yield	-10.9%	-9.5%	-8.7%	-7.8%	-7.9%	-2.7%
Enterprise value	$1.2B	$998.5M	$1.1B	$1.1B	$432.8M	$1.1B
Net debt / EBITDA	0.39×	1.97×	-0.48×	-0.33×	0.05×	0.18×
Cash conversion cycle (days)	-107	-129	-248	20	0	0